Chronic high-dosage androgen administration to ovulatory women does not alter adrenocortical steroidogenesis

Futterweit, Walter; Green, Georgette; Tarlin, Nancy; Dunaif, Andrea

doi:10.1016/0020-7292(93)90869-x

Cited by 5 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No change in ACTH responsiveness was seen when some of these hyperandrogenic women were treated with a GnRH agonist, suppressing their ovarian hormone production. In a recent study , Futterweit et al (1992) found no significant changes in ACTH response after 6 months of testosterone administration in four transsexual patients.…”

Section: Discussionmentioning

confidence: 86%

“…Some in-vitro evidence also suggests that androgens might affect the activity of various enzymes in the adrenal gland (Yates & Deshpande, 1974;Sharma et al, 1963;Toscano et aZ., 1990). However, in a recent study in four transsexual patients treated with testosterone esters, no change in maximal adrenal response to ACTH was observed during treatment (Futterweit et al, 1992).…”

mentioning

confidence: 86%

See 1 more Smart Citation

Testosterone administration increases adrenal response to adrenocorticotrophin

Polderman

Gooren

Veen

1994

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 86%

mentioning

confidence: 86%

Testosterone administration increases adrenal response to adrenocorticotrophin

Polderman

Gooren

Veen

1994

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…Some of the effects of long-term T administration in young, non-obese, female subjects include increased visceral fat [35]. T treatment also significantly reduced adiponectin serum levels in FMT [30] but this treatment did not significantly alter lipid profiles or adrenal steroidogenesis [46]. Furthermore, Perrone et al [31] showed that exogenous T administration did not stimulate endometrial proliferation in FMT and may even exert atrophic effects on the endometrium.…”

Section: Studies Of Pharmacological T Therapy In Fmtsmentioning

confidence: 99%

Safety of Physiological Testosterone Therapy in Women: Lessons from Female-to-Male Transsexuals (FMT) Treated with Pharmacological Testosterone Therapy

Traish

Gooren

2010

The Journal of Sexual Medicine

View full text Add to dashboard Cite

Introduction The safety of long-term physiological doses of testosterone (T) therapy in women with sexual dysfunction is a contentious issue, in part, because of fear of adverse effects, such as breast cancer, vascular disease, and excessive virilization. This unsubstantiated fear has hampered progress in treating women with sexual dysfunction using T therapy in physiological doses to achieve circulating levels in the normal range. Aim To examine evidence derived from studies in female-to-male transsexuals (FMT) treated with supraphysiological (pharmacological) doses of T for long periods of time with no apparent major adverse effects. Methods A comprehensive literature search of relevant articles published between 1980 and 2010 pertaining to the topic of T in FMTs was performed using PubMed. The following key words were used: female-to-male transsexuals; testosterone; virilization; gender re-assignment; and androgen therapy in women. Relevant articles were retrieved, reviewed, and the information was analyzed and evaluated for study methodology and major findings. Main Outcome Measures Data from peer-reviewed publications were critically analyzed and the information was summarized. Results The data from the studies reported in the literature to date strongly suggest that treatment of FMTs with supra-physiological doses of T had minimal adverse effects. No increase in mortality, breast cancer, vascular disease, or other major health problems were reported. Conclusions No significant serious adverse effects were reported in FMTs treated with pharmacological doses of T. In light of the findings with supraphysiological doses of T, we suggest that treatment with T at doses producing physiological levels in women with sexual dysfunction are expected to produce limited and minimal adverse effects.

show abstract

“…Some investiga tors have observed a decrease in 3β-HSD activity following estrogen administration in hypoestrogenic women, while others have not observed a change. 16 Studying the effect of androgens, we 17 and others 18 have been unable to demonstrate a signifi cant change in the activity of this enzyme in vivo. Interestingly, Gonzalez and coworkers reported nor malization of adrenocortical activity in two patients presumed to be 3β-HSD deficient, following three months of gonadotropin-releasing hormone agonist suppression.…”

Section: β-Hydroxysteroid Dehydrogenase Deficiencymentioning

confidence: 84%

Adrenocortical Dysfunction in Androgen Excess

Azziz¹

1993

Semin Reprod Med

View full text Add to dashboard Cite

Chronic high-dosage androgen administration to ovulatory women does not alter adrenocortical steroidogenesis

Cited by 5 publications

References 17 publications

Testosterone administration increases adrenal response to adrenocorticotrophin

Testosterone administration increases adrenal response to adrenocorticotrophin

Safety of Physiological Testosterone Therapy in Women: Lessons from Female-to-Male Transsexuals (FMT) Treated with Pharmacological Testosterone Therapy

Adrenocortical Dysfunction in Androgen Excess

Contact Info

Product

Resources

About